Key result
SGLT2 inhibitors reduce composite renal events ~28% in patients with heart failure.
Why the study?
SGLT2 inhibitors are an integral part of HF therapy, and this study aimed to elucidate their longer-term effect on renal function in HF patients for comparison with existing data in CKD and T2DM.
Do SGLT2 inhibitors reduce composite renal events and acute kidney injury in patients with heart failure?
Meta-Analysis (n=90,413)
Do SGLT2 inhibitors reduce composite renal events and acute kidney injury in patients with heart failure?
In patients with heart failure, SGLT2 inhibitors significantly reduce the risk of composite renal outcomes by 28% and acute kidney injury by 25% over a median follow-up of 2.3 years.
Answers are grounded in this paper and cite their sources.
Supports SGLT2 inhibitor use for renal protection in heart failure; extends prior benefits from CKD and diabetes to this population.
Aims Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an integral part of heart failure (HF) therapy. The purpose of this study was to elucidate the effect of SGLT2 inhibitors on renal function, in HF patients, over longer-term follow-up. This could be compared to existing data in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus T2DM. Methods A systematic review and meta-analysis was conducted in patients with HF treated with SGLT2 inhibitor (PROSPERO ID: CRD42024562311). Searches were performed across five databases from inception to 31 October 2024 identifying randomised controlled trials. Included studies were appraised using the Cochrane Risk of Bias tool. Two primary outcomes were investigated, composite renal event and AKI (acute kidney injury). Relative risk (RR) was pooled with 95% CI using the statistical software ‘R’. Results Thirteen trials involving 90,413 participants were included. Median follow-up was 2.3 years, and data of 32,957 patients with HF was extracted. In patients with HF, SGLT2 inhibition reduced renal specific composite outcomes by 28% (RR 0.72; 95% CI 0.57-0.91). Additionally, AKI was reduced in HF patients taking SGLT2 inhibitors (RR 0.75; 95% CI 0.65-0.86). Subgroup analysis showed no differences in patients with and without HF, or when stratified by baseline renal function. Conclusion These results encourage use of SGLT2 inhibitors to retard progression of kidney disease and AKI. This benefit was seen in all trials, irrespective of concurrent comorbidities. Despite the acute dip in eGFR, SGLT2 inhibitors should be continued to maximise benefit, even in patients with HF.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2026) conducted a meta-analysis in Heart failure (n=90,413). SGLT2 inhibitors was evaluated on Composite renal event and acute kidney injury (AKI) (RR 0.72, 95% CI 0.57-0.91). SGLT2 inhibitors in patients with heart failure reduced composite renal events and acute kidney injury.
Synapse has enriched 10 related papers. Consider them for comparative context: